PharmiNews

The Directory of Pharma Companies and News

Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading device and formulation business for inhaled airways products. With our extensive range of technologies, integrated capabilities and collaborations, we are a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC. Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer, Chiesi, Almirall, Janssen, and Tianjin KingYork.
Category: Biotech
Category: Biotech

Vectura News

DateNews
2017-01-11Pre-close update
2017-01-10Vectura to present at the 35th Annual J.P. Morgan Healthcare Conference
2016-12-23Global development programme with Mundipharma for pMDI inhaled triple therapy (VR2076) for asthma and COPD
2016-12-22VR876 – confirmation of alternative nebulised delivery device for Bayer’s Ventavis (iloprost) using adapted Vectura FOX®...
2016-12-21Licensing agreement signed for the launch of Utibron/Seebri in the US
2016-12-08Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment
2016-10-18Notice of Interim Results
2016-09-07Results of the Annual General Meeting
2016-09-07AGM trading update
2016-09-05New findings confirm Ultibro® Breezhaler® consistently more effective than Seretide® in reducing COPD flare-ups across d...
2016-08-31AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus® in persistence to treatment
2016-08-30Update on Mundipharma’s European Phase III trial of flutiform® in COPD and latest flutiform® in-market sales
2016-08-05US$8 million Exparel® sales milestone from Pacira triggered
2016-07-27Vectura initiates legal proceedings against GSK relating to option-to-licence patent agreement and confirms 2016 revenue...
2016-07-22Change of accounting reference date
2016-07-08Dr John Brown, Non-Executive Director, confirms date to step down
2016-07-05Board Committee changes post completion of merger with Skyepharma
2016-07-01Lyon manufacturing facility returns to the Vectura Group
2016-06-30Licence Option Exercised
2016-06-10Company Act 2006 S430 (2B) Disclosure
2016-06-03Vectura reports successful completion of VR942 Phase I clinical study
2016-05-26Vectura Group plc – Preliminary Results for twelve months ending 31 March 2016
2016-05-24Vectura and Propeller Health announce collaboration to develop digitally-connected inhalers to address chronic respirato...
2016-05-03Ablynx reports positive top line results Phase I-IIa study
2016-04-08VR315 US ANDA for Generic Advair Diskus® accepted for filing by FDA and milestone payment
2016-02-10VR315 US – Clinical Study Report final, triggers milestone payment
2016-01-08VR315 US completes clinical study
2015-12-18Ablynx’s anti-RSV Nanobody® completes enrolment of the first-in-infant Phase I/IIa safety study and extends the trial fo...
2015-12-09Commencement of first Phase III trial of inhaled triple therapy QVM149 for asthma and milestone payment
2015-11-17FLAME study shows superiority of Novartis’ Ultibro® Breezhaler® over Seretide® in reducing COPD exacerbations
2015-11-17Vectura Group plc - Interim Results for the six months ended 30 September 2015
2015-10-30US FDA approves new dual combination bronchodilator Utibron™ Neohaler® and stand-alone monotherapy Seebri™ Neohaler® for...
2015-10-30VR632 EU development milestone
2015-10-17Notification of Interim Results
2015-10-02VR876 – Progress in Europe confirmed
2015-09-24Results of General Meeting and Appointment of CEO
2015-07-28Pre-IND meeting with the US FDA regarding VR647
2015-06-18Planned development of QVM149 for asthma
2015-06-16Director declaration
2015-06-15Annual Report and Accounts 2015
2015-06-04VR942 Phase I clinical study commences
2015-05-20Vectura Group plc – Preliminary Results for the year ended 31 March 2015
2015-04-14Gemünden - Planned Closure
2015-04-01Appointment of Non-Executive Director
2015-03-11AirFluSal launched in Portugal & Ireland
2015-03-05NDA acceptance for QVA149 and NVA237
2015-02-03Chief Executive’s intention to step down
2015-01-09Vectura to present at JP Morgan Conference
2015-01-08US Submission for NVA237 and QVA149
2015-01-06Development and licence agreement with Janssen
2015-01-06Vectura signs global development and licence agreement with Janssen in asthma/COPD
2014-11-18Vectura Group plc - Interim Results for the six months ended 30 September 2014
2014-08-19Vectura Group plc - Interim Management Statement
2014-06-30Vectura announces a further US collaboration agreement with a leading international pharmaceutical company for the VR506...
2014-06-24VR315 US development milestone
2014-05-21Positive results for once-daily Ultibro® Breezhaler® versus combination therapy (tiotropium plus formoterol)
2014-05-21Vectura Group plc – Preliminary Results for the year ended 31 March 2014
2014-04-01The smart nebuliser FOX wins Red Dot Design Award
2014-03-13Acquisition of Activaero
2014-02-28South Korean Regulatory Authority confirm approval of AirFluSal® Forspiro®
2014-02-12Belgian Regulatory Authority confirm approval of AirFluSal® Forspiro®
2014-02-10Norwegian Regulatory Authority confirm approval of AirFluSal® Forspiro®
2014-01-14Swedish Regulatory Authority confirm approval of AirFluSal® Forspiro®
2014-01-13German Regulatory Authority confirm approval of AirFluSal® Forspiro®
2014-01-09Vectura to Present at the 32nd Annual J.P. Morgan Healthcare Conference, San Francisco
2013-12-18Update - Danish Regulatory Authority confirm approval of AirFluSal® Forspiro®
2013-12-18Danish Regulatory Authority confirm approval of AirFluSal® Forspiro®
2013-11-19Vectura Group plc - Interim Results for the six months ended 30 September 2013
2013-11-14Bruno Angelici joins the Board of Vectura
2013-09-30Vectura and UCB to collaborate and share expertise in severe inflammatory disease
2013-09-23Ultibro Breezhaler (QVA149) approved in Europe
2013-09-23Board Announcement - Jack Cashman to retire as Non-Executive Chairman
2013-09-23Result of AGM
2013-09-20Approval of once-daily dual bronchodilator Ultibro® Inhalation Capsules in Japan (QVA149) for the treatment of COPD
2013-09-04Presentations at ERS
2013-07-26Ultibro® Breezhaler® gains positive CHMP opinion
2013-06-19Vectura to Present at J.P. Morgan European Healthcare Conference 24th June 2013
2013-06-04Vectura Group plc – Potential royalty and milestone payments on Fibrocaps™
2013-05-29New study finds ADEPT® effective in reducing Adhesions following Gynecological Laparoscopic Surgery
2013-05-29Vectura Group plc - Date of announcement of interim results for the six months ended 30 September 2007
2013-05-29Jefferies 2013 Global Healthcare Conference
2013-05-21Board change
2013-05-21Vectura Group plc – Preliminary Results for the year ended 31 March 2013
2013-05-21New data presented at the American Thoracic Society meeting highlights strength of once-daily COPD portfolio in improvin...
2013-05-13Vectura establishes strategic partnership (Kinnovata) for new respiratory business in China
2013-05-09Notice of Results
2013-04-25Appointment of Joint Broker
2013-02-20Vectura to Present at Citi 2013 Global Healthcare Conference
2013-01-07Vectura to present at the 31st Annual J.P. Morgan Healthcare Conference
2012-11-20Vectura Group plc - Interim Results for the six months ended 30 September 2012
2012-11-07QVA149 marketing application filed in Japan for once-daily maintenance treatment of COPD
2012-10-26Date of announcement of Interim Results for six months ended 30 September 2012
2012-10-01The European Commission approves once-daily Seebri® Breezhaler® as maintenance COPD treatment in the European Union
2012-09-28Approval for once-daily Seebri® Inhalation Capsules as maintenance COPD treatment in Japan
2012-09-25QVA149 is filed as a treatment for COPD in Europe
2012-09-18Results of the Annual General Meeting held on 18 September 2012
2012-09-03Data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA1...
2012-08-30QVA149 Phase III study meets primary endpoint in reducing exacerbations in COPD patients, filing in EU and Japan by end ...
2012-08-30Multiple presentations of clinical data on NVA237 and QVA149 at the European Respiratory Society Annual Congress, Vienna...
2012-08-28Notice of AGM
2012-08-15Vectura appoints Corporate Development Director
2012-08-15Vectura Group plc - Interim Management Statement & VR315 US development milestone
2012-06-22Once-daily Seebri® Breezhaler® receives positive CHMP opinion to treat COPD patients in the EU
2012-05-17NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD pati...
2012-05-03Vectura's Chief Operations Officer appointed to the Board
2012-04-26Vectura Group plc - Preliminary Results
2012-04-24QVA149 ILLUMINATE Phase III COPD study meets primary endpoint and clarification of anticipated timing of US filings for ...
2012-01-11Vectura Group plc – Interim Management Statement
2011-11-25Novartis files NDA for NVA237 as a treatment for chronic obstructive pulmonary disease (COPD) in Japan
2011-11-14Vectura Group plc - Interim Results for the six months ended 30 September 2011
2011-10-31Date of announcement of Interim Results for the six months ended 30 September 2011
2011-10-25Update on US NDA timelines for NVA237 and QVA149
2011-09-27NVA237 filed in Europe and positive Phase III data at European Respiratory Society Congress
2011-08-05Vectura enters License Agreement for the development and marketing of VR315 in RoW territories
2011-08-03Vectura announces a new US collaboration agreement with a leading international pharmaceutical company for the VR315 com...
2011-07-22Vectura Group plc: Interim Management Statement
2011-07-22Results of the Annual General Meeting held on 22 July 2011
2011-06-30Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in C...
2011-06-28Notice of Annual General Meeting, Availability of 2010/11 Annual Report and Change to the Board of Directors
2011-05-16Date of announcement of Preliminary Results for year ended 31 March 2011
2011-04-19Phase III data show NVA237 significantly improves lung function with good safety profile in COPD patients
2011-03-25VR496 demonstrates anti-inflammatory and mucolytic activity in cystic fibrosis patients
2011-02-01Appointment of Corporate Broker
2011-01-19Vectura appoints Neil Warner as Non-Executive Director and Chair of the Audit Committee
2010-11-16Positive outcome for VR040 in Parkinson’s trial
2010-10-21Update on NVA237 and QVA149 & Achievement of a development milestone for VR632
2010-09-22Results of the Annual General Meeting held on 22 September 2010
2010-08-06Vectura and GlaxoSmithKline sign agreement to license some of Vectura’s dry powder drug formulation patents
2010-08-03Interim Management Statement
2010-05-21NVA237 Phase II Data at the American Thoracic Society Meeting
2010-05-18Vectura & Sandoz revise VR315 agreement
2010-05-10Vectura announces start of Phase III clinical study with QVA149
2010-05-10Vectura close period trading update
-0001-11-30Appoints James Ward-Lilley as CEO
-0001-11-30Vectura announces a further collaboration with Hikma for the development of generic salmeterol for the US (VR730)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.